Pancreatic ductal adenocarcinoma is a highly aggressive malignancy with a poor prognosis.Effective treatment with acceptable outcomes is yet to be found,with chemo-and radioresistance comprising major impediments towa...Pancreatic ductal adenocarcinoma is a highly aggressive malignancy with a poor prognosis.Effective treatment with acceptable outcomes is yet to be found,with chemo-and radioresistance comprising major impediments towards this goal.Although upfront surgery is the established therapeutic approach for resectable and borderline resectable disease,neoadjuvant treatment has recently monopolized the interest in clinical trials.This also applies to locally advanced pancreatic adenocarcinomas that could potentially be rendered operable.Chemotherapy and chemoradiotherapy are the most utilized therapeutic modalities in the neoadjuvant setting,while immunotherapy and targeting agents have been gaining significant attention.This critical review focuses on the clinical experience gained from retrospective and phase II/III randomized trials,reporting on the outcomes of neoadjuvant chemotherapy and chemoradiotherapy for pancreatic adenocarcinoma.Moreover,the ongoing trials,including those that involve immunotherapy and targeting agents,are summarized.展开更多
文摘Pancreatic ductal adenocarcinoma is a highly aggressive malignancy with a poor prognosis.Effective treatment with acceptable outcomes is yet to be found,with chemo-and radioresistance comprising major impediments towards this goal.Although upfront surgery is the established therapeutic approach for resectable and borderline resectable disease,neoadjuvant treatment has recently monopolized the interest in clinical trials.This also applies to locally advanced pancreatic adenocarcinomas that could potentially be rendered operable.Chemotherapy and chemoradiotherapy are the most utilized therapeutic modalities in the neoadjuvant setting,while immunotherapy and targeting agents have been gaining significant attention.This critical review focuses on the clinical experience gained from retrospective and phase II/III randomized trials,reporting on the outcomes of neoadjuvant chemotherapy and chemoradiotherapy for pancreatic adenocarcinoma.Moreover,the ongoing trials,including those that involve immunotherapy and targeting agents,are summarized.
